Neurocrine Biosciences (NBIX) Cash & Equivalents Growth (3y) (2013 - 2026)
Neurocrine Biosciences (NBIX) Cash & Equivalents Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.81 Bn | 42.84 Bn | - | 21.81% |
| 2 | Teva Pharmaceutical Industries | 43.29 Bn | 39.63 Bn | 2.15 Bn | 11.05% |
| 3 | Zoetis | 31.59 Bn | 29.91 Bn | 1.05 Bn | -4.92% |
| 4 | Takeda Pharmaceutical | 28.67 Bn | 22.88 Bn | 5.10 Bn | 7.80% |
| 5 | United Therapeutics | 22.24 Bn | 19.58 Bn | 683.80 Mn | 19.10% |
| 6 | Viatris | 18.79 Bn | 17.91 Bn | 1.46 Bn | 12.11% |
| 7 | Neurocrine Biosciences | 15.71 Bn | 15.32 Bn | 935.80 Mn | 27.55% |
| 8 | Elanco Animal Health | 12.09 Bn | 11.56 Bn | 798.00 Mn | 13.03% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | 32.82% |
| 10 | Alkermes | 8.19 Bn | 7.53 Bn | 397.90 Mn | -8.41% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 27.55% |
| Mar 31, 2026 | 36.93% |
| Dec 31, 2025 | 38.10% |
| Sep 30, 2025 | 17.04% |
| Jun 30, 2025 | 17.37% |
| Mar 31, 2025 | -10.44% |
| Dec 31, 2024 | -12.18% |
| Sep 30, 2024 | 3.92% |
| Jun 30, 2024 | -27.59% |
| Mar 31, 2024 | 3.97% |
| Dec 31, 2023 | 10.83% |
| Sep 30, 2023 | -11.61% |
| Jun 30, 2023 | -27.19% |
| Mar 31, 2023 | -18.28% |
| Dec 31, 2022 | 32.83% |
| Sep 30, 2022 | 8.39% |
| Jun 30, 2022 | 5.02% |
| Mar 31, 2022 | 54.84% |
| Dec 31, 2021 | 34.39% |
| Sep 30, 2021 | 16.70% |